Joel A, Mathew N, Andugala SS, Daniel S, Gnanamuthu BR, John AO, Georgy JT, Chacko RT, Irodi A, Yadav B, John S, Singh A. Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting. Ecancermedicalscience. 2021 Feb 11;15:1186. doi: 10.3332/ecancer.2021.1186. PMID: 33777179; PMCID: PMC7987494. Link

Joel A, Georgy JT, Thumaty DB, John AO, Chacko RT, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Jacob PM, Sebastian P, Backianathan S, Singh A. Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India. Ecancermedicalscience. 2021 Mar 19;15:1207. doi: 10.3332/ecancer.2021.1207. PMID: 33912232; PMCID: PMC8057782.

Georgy JT, Mathuram AJ, George AA, Chandramohan J. Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp. BMJ Case Rep. 2017 Aug 18;2017:bcr2017220913. doi: 10.1136/bcr-2017-220913. PMID: 28824000; PMCID: PMC5623300.

Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ, Iyadurai R. Evans syndrome and immune thrombocytopenia in two patients with COVID-19. J Med Virol. 2021 May;93(5):2642-2644. doi: 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID:

Sharma P, Georgy JT, Andrews AG, John AO, Joel A, Chacko RT, Premkumar PS, Singh A. Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome. Support Care Cancer. 2022 Mar 21:1–8. doi: 10.1007/s00520-022-06970-2. Epub ahead of print. PMID: 35314996; PMCID: PMC8937495.

Georgy JT, Singh A, John AO, Joel A, Andrews AG, Thumaty DB, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Backianathan S, Chacko RT. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy. Klin Onkol. 2021 Winter;34(1):49-55. English. doi: 10.48095/ccko202149. PMID: 33657819.

Joel A, Mathew N, Andugala SS, Daniel S, Gnanamuthu BR, John AO, Georgy JT, Chacko RT, Irodi A, Yadav B, John S, Singh A. Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting. Ecancermedicalscience. 2021 Feb 11;15:1186. doi: 10.3332/ecancer.2021.1186. PMID: 33777179; PMCID: PMC7987494. Link

Joel A, Georgy JT, Thumaty DB, John AO, Chacko RT, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Jacob PM, Sebastian P, Backianathan S, Singh A. Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India. Ecancermedicalscience. 2021 Mar 19;15:1207. doi: 10.3332/ecancer.2021.1207. PMID: 33912232; PMCID: PMC8057782.

Georgy JT, Mathuram AJ, George AA, Chandramohan J. Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp. BMJ Case Rep. 2017 Aug 18;2017:bcr2017220913. doi: 10.1136/bcr-2017-220913. PMID: 28824000; PMCID: PMC5623300.

Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ, Iyadurai R. Evans syndrome and immune thrombocytopenia in two patients with COVID-19. J Med Virol. 2021 May;93(5):2642-2644. doi: 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID:

Sharma P, Georgy JT, Andrews AG, John AO, Joel A, Chacko RT, Premkumar PS, Singh A. Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome. Support Care Cancer. 2022 Mar 21:1–8. doi: 10.1007/s00520-022-06970-2. Epub ahead of print. PMID: 35314996; PMCID: PMC8937495.

Georgy JT, Singh A, John AO, Joel A, Andrews AG, Thumaty DB, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Backianathan S, Chacko RT. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy. Klin Onkol. 2021 Winter;34(1):49-55. English. doi: 10.48095/ccko202149. PMID: 33657819.

Joel A, Mathew N, Andugala SS, Daniel S, Gnanamuthu BR, John AO, Georgy JT, Chacko RT, Irodi A, Yadav B, John S, Singh A. Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting. Ecancermedicalscience. 2021 Feb 11;15:1186. doi: 10.3332/ecancer.2021.1186. PMID: 33777179; PMCID: PMC7987494.

Singh A, Thomas Georgy J, Dhananjayan S, Sigamani E, Oommen John A, Joel A, Chandramohan J, Abarna R, Rebekah G, Backianathan S, Thomas Abraham D, Jacob Paul M, Titus Chacko R, Therese Manipadam M, Pai R. Comparative Analysis of Mutational Patterns in Triple Negative Breast Cancer Before and after Neoadjuvant Chemotherapy in Patients with Residual Disease. Gene. 2023 Nov 9:147980. doi: 10.1016/j.gene.2023.147980. Epub ahead of print. PMID: 37951371.

Thumaty DB, Chacko RT, John AO, Joel A, Georgy JT, Jacob M, Samarasam I, Masih D, Isaiah R, Jeyaseelan V, Singh A. Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma. Ecancermedicalscience. 2021 Sep 21;15:1292. doi: 10.3332/ecancer.2021.1292. PMID: 34824615; PMCID: PMC8580596.

John AO, Singh A, Bala D, Joel A, Georgy JT, Jesudasan MR, Mittal R, Ram TS, Reddy JR, Murthy A, Chandramohan A, Eapen A, Masih D, Ramnath N, Dobrosotskaya I, Yadav B, Chacko RT. Total Neoadjuvant Therapy (TNT) with Full Dose Concurrent Chemotherapy in Locally Advanced Rectal Adenocarcinoma Including Signet Ring and Mucinous Cancers. J Gastrointest Cancer. 2023 Jul 21. doi: 10.1007/s12029-023-00941-4. Epub ahead of print. PMID: 37479897.

Joel A, Singh A, Hepzibah J, Devasia A, Kumar S, Gnanamuthu BR, Chandramohan A, George AJP, John NT, Yadav B, John AO, Georgy JT, John S, Chacko RT. End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention? South Asian J Cancer. 2022 Aug 22;11(4):315-321. doi: 10.1055/s-0041-1735480. PMID: 36756102; PMCID: PMC9902077.

S B MJ, Chacko B, Selvarajan S, Peter JV, Geevar T, Dave RG, Georgy JT, Zachariah A, George T, Sathyendra S, Hansdak SG, Krishnaswami RK, Thangakunam B, Gupta R, Karuppusami R, Nair SC, Srivastava A. Biomarkers of coagulation, endothelial, platelet function, and fibrinolysis in patients with COVID-19: a prospective study. Sci Rep. 2024 Jan 23;14(1):2011. doi: 10.1038/s41598-024-51908-9. PMID: 38263377; PMCID: PMC10805716.

Singh A, Georgy JT, Joel A, Thumaty DB, John AO, Ramnath N, George TK, Sharma P, Patole S, Rebekah G, Sigamani E, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Sebastian P, Backianathan S, Chacko RT. Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer. Cancer Invest. 2023 Oct;41(9):789-802. doi: 10.1080/07357907.2023.2278048. Epub 2023 Nov 17. PMID: 37909664.

Thomas Z, Georgy JT, Ponmar M, Thumaty DB, Prabhu AJ, Singh A. Metastatic Malignant Pseudomyogenic Hemangioendothelioma: An Exceedingly Rare Entity That Challenges Conventional Paradigms. Int J Surg Pathol. 2025 Jun;33(4):945-950. doi: 10.1177/10668969241286068. Epub 2024 Oct 1. PMID: 39350761.

Sebastian R, Georgy JT, George A, Santhanam P, Philip R, Joel A, John AO, Philip DSJ, Thumaty DB, Kodiatte TA, Singh A, Pai R. Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer. Ecancermedicalscience. 2025 Aug 15;19:1966. doi: 10.3332/ecancer.2025.1966. PMID: 41333367; PMCID: PMC12665903.

Georgy JT, Regi SS, Georgy RV, Sasidharan BK, Joel A, Philip DSJ, John AO, Thumaty DB, Marimuthu PK, Jambunathan P, Harikrishna K, Thomas Z, Rani NJ, Tirkey AJ, Thomas M, Isiah R, Singh A. Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Sci Rep. 2025 Oct 8;15(1):35110. doi: 10.1038/s41598-025-19197-y. PMID: 41062634; PMCID: PMC12508025.

Marimuthu PK, Georgy JT, Philip DSJ, John AO, Joel A, Thumaty DB, Chacko RT, Jambunathan P, Thomas Z, Harikrishna K, Isiah R, Pavamani SP, Sasidharan B, Mathew M, Alex Kodiatte T, Irodi A, Thangakunam B, Isaac BTJ, Gupta R, Rani J, Singh A. Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis. JCO Glob Oncol. 2025 Mar;11:e2400256. doi: 10.1200/GO-24-00256. Epub 2025 Mar 24. PMID: 40127380.